ANKRD11 is altered in 3.19% of all cancers with colon adenocarcinoma, endometrial endometrioid adenocarcinoma, prostate adenocarcinoma, breast invasive ductal carcinoma, and lung adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in ANKRD11 are ANKRD11 Loss (0.34%), ANKRD11 Amplification (0.05%), ANKRD11 K1461del (0.03%), ANKRD11 R2579C (0.02%), and ANKRD11 A2017T (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.